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summARy – A patient with development of autoimmune hyperthyroidism following radioio-
dine treatment for autonomously functioning thyroid adenoma is presented. This is a rare occurren-
ce, probably as a consequence of shedding of the thyroid-stimulating hormone receptor, which is a 
source of antigen leading to activation of the autoimmune response in susceptible individuals.
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Introduction 
Radioiodine is the treatment of choice for the hy-
perthyroidism caused by autonomously functioning 
thyroid adenoma. side effects of such a treatment are 
few and primarily include radioactive thyroiditis (<5% of 
patients), while development of Graves’ disease occurs 
rarely, in less than 2% of treated patients. The molecu-
lar basis of thyroid hyperfunction lays in point genetic 
mutations and/or antibody-induced structural changes 
of the thyroid-stimulating hormone receptor (tshR), 
which appears to have unstable molecular integrity and 
thus propensity to overactivity1. in this case report, we 
describe development of persistent autoimmune hyper-
thyroidism in a patient treated with radioiodine for the 
hyperfunctioning thyroid adenoma. 
Case Report
A 49-year-old female patient reported to our de-
partment for the symptoms of hyperthyroidism and 
palpable thyroid nodule. initial diagnostic algorithm 
confirmed the early onset hyperthyroidism (t3 3.0, t4 
92, and tsh 0.008) (table 1) and thyroid scintiscan 
was indicative of toxic adenoma in the right thyroid 
lobe (fig. 1a). The patient received radioiodine treat-
ment (21 mCi J-131) and after 4-month follow-up eu-
thyroidism was achieved (t3 2.2, t4 84, and tsh 
1.87) (table 1), suggesting curative effect of radio-
iodine. twelve months later, the patient’s symptoms 
recurred, but this time thyroid scintiscan unexpect-
edly suggested increased radioiodine accumulation in 
the left thyroid lobe (fig. 1b), while endocrinological 
findings were suggestive of recurrent hyperthyroidism 
(t3 2.6, t4 127, tsh <0.002) (table 1). The patient 
was treated with beta-blockers until the etiology of 
hyperthyroidism was confirmed. After six months 
of treatment, the symptoms were well controlled but 
repeated thyroid scintiscan undoubtedly confirmed 
diffuse, more intense radioiodine accumulation in the 
left thyroid lobe, a finding specific for autoimmune 
hyperthyroidism (fig. 1c). This was supported by the 
laboratory finding of positive anti-tpo antibodies 
(338) and anti-tg-antibodies (134), increased thyroid 
hormones (t3 3.5 and t4 166) and suppressed tsh 
(<0.004) (table 1). tR-Ab was slightly positive (3.4). 
mmi in lower dose was introduced for a short time 
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until euthyroidism was achieved (t3 2.4, t4 98, tsh 
0.25) (table 1). finally, two years after initial radioio-
dine treatment, the patient received J-131 (8 mCi) once 
again. now she is hypothyroid, receiving replacement 
levothyroxine treatment (75 mcg of levothyroxine).
Discussion 
hyperthyroidism is a relatively common thyroid 
disorder occurring in 0.77/1000 female and 0.18/1000 
male patients. most commonly it is a symptom of 
autoimmune, Graves’ disease, while other causes, 
including autonomous, toxic adenoma or toxic mul-
tinodular goiter are less frequent2. up to 9% of hyper-
thyroid patients with nodular hyperfunctioning goiter 
(either multinodular or with a single hyperfunction-
ing node) also have positive tRAb, making it difficult 
to distinguish the true etiology of hyperthyroidism. 
in rare patients with marine-lenhart syndrome, au-
toimmunity and autonomy of thyroid nodules coexist 
in the same patient3,4. According to scarce literature 
reports, transition from autonomously functioning 
thyroid nodules to autoimmune hyperthyroidism can 
result from therapeutic manipulation of the gland, ei-
ther following radioiodine5 or thyroid surgery6, or can 
be a consequence of nodule degradation caused by in-
farction7. it is probably a direct consequence of shed-
ding of the tshR ectodomain, providing a source of 
antigen and activating the autoimmune response in 
prone/susceptible individuals1. our patient’s findings 
showed the occurrence of atypical Graves’ disease 
following radioiodine treatment and development of 
anti-tpo, anti-tGA antibodies and to a lesser extent 
tRAb. This may be due to a smaller thyroid size be-
cause of the previous radioiodine treatment. unlike 
true Graves’ disease, clinical presentation was mild 
and thyroid hormones only slightly elevated. The pos-
sible cause is probably radioiodine treatment, which 
may have triggered the autoimmune response, turn-
ing a toxic nodule into Graves’ disease. we conclude 
that in particular patients susceptible to autoimmu-
nity, the release of antigenic materials secondary to 
thyroid destruction during radioiodine treatment can 
trigger an autoimmune thyroid response and lead to 
Graves’ disease development. patients may then have 
a milder and gradual course of disease with attenuated 
symptoms.
Table 1. Thyroid hormone levels during the course of treatment
timeline t3  (nmol/l) t4 (nmol/l) tsh  (miu/l)
initial 3.0 92 0.008
4 months following 1st i131 application 2.2 84 1.87
12 months following i131 2.6 127 <0.002
1.5 year following i131 3.5 166 <0.004
following 2nd i131 application 2.4 98 0.25
Fig. 1. (a) Toxic adenoma of the right thyroid lobe and 
suppressed uptake of radioiodine in the adjacent normal 
gland on initial scintiscan; (b) post-radioiodine scintiscan 
with diffuse positivity of the left thyroid lobe and to a 
lesser extent right thyroid lobe; (c) thyroid scintiscan after 
1.5 year with further progression of the uptake in the left 
thyroid lobe.
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sažetak
RAZvoJ GRAvesove Bolesti nAKon liJeČenJA toKsiČnoG ADenomA ApliKACiJom i131
J. Martinko, M. Cigrovski-Berković, B. Bečejac, D. Solter i M. Solter
prikazuje se slučaj bolesnice u koje se nakon aplikacije i131 za liječenje toksičnog adenoma razvila Gravesova bolest. 
Razvoj autoimune bolesti nakon terapije radiojodom nije uobičajeni slijed, a najvjerojatnije je posljedica otkrivanja antige-
nih domena na tsh-receptoru koje nastaju kao posljedica njegove manipulacje.
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